Breaking News Instant updates and real-time market news.

FIII

Forum Merger III

$13.41 /

+0.63 (+4.93%)

, ELMS

Electric Last Mile Solutions

$0.00 /

+ (+0.00%)

14:41
01/26/21
01/26
14:41
01/26/21
14:41

ELMS says 'ready to answer' President Biden's call to replace fleet with EVs

Electric Last Mile Solutions said via Facebook that, "'The federal government maintains a fleet of 645,000 vehicles...' ELMS is ready to answer the call. Mishawaka plant is capable of producing 100k #AmericanMade EVs annually! " Electric Last Mile, or ELMS, an electric vehicle, or EV, company focused on creating last mile solutions, and Forum Merger III announced on December 11 that they had entered into a definitive agreement for a business combination that would result in ELMS becoming a publicly listed company.Reference Link

FIII

Forum Merger III

$13.41 /

+0.63 (+4.93%)

ELMS

Electric Last Mile Solutions

$0.00 /

+ (+0.00%)

TODAY'S FREE FLY STORIES

Hot Stocks
Fly Intel: Top five weekend stock stories » 20:03
02/28/21
02/28
20:03
02/28/21
20:03
JNJ

Johnson & Johnson

$158.52 /

-4.28 (-2.63%)

, BRK.B

Berkshire Hathaway

$240.27 /

-3.35 (-1.38%)

, BRK.A

Berkshire Hathaway

$364,420.00 /

-4355 (-1.18%)

, ROST

Ross Stores

$116.65 /

-2.08 (-1.75%)

, TWLO

Twilio

$392.84 /

+15.295 (+4.05%)

, CG

Carlyle Group

$34.24 /

-0.22 (-0.64%)

, AEP

American Electric

$74.88 /

-1.43 (-1.87%)

, D

Dominion

$68.29 /

-2.31 (-3.27%)

, ETR

Entergy

$86.82 /

-1.26 (-1.43%)

, EXC

Exelon

$38.60 /

-0.32 (-0.82%)

, NEE

NextEra Energy

$73.51 /

-0.55 (-0.74%)

, C

Citi

$65.86 /

-1.54 (-2.28%)

, DOW

Dow Inc.

$59.32 /

-2.055 (-3.35%)

, ASOMY

Asos

$0.00 /

+ (+0.00%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The Food and Drug Administration issued an emergency use authorization for the third vaccine for the prevention of coronavirus disease. The EUA allows Johnson & Johnson's (JNJ) Janssen COVID-19 vaccine to be distributed in the U.S for use in individuals 18 years of age and older. Meanwhile, Johnson & Johnson also announced that the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has recommended its single-shot COVID-19 vaccine. The ACIP recommendation will be forwarded to the Director of the CDC and the U.S. Department of Health and Human Services for review and adoption. Johnson & Johnson has begun shipping its COVID-19 vaccine and expects to deliver enough single-shot vaccines by the end of March to enable the full vaccination of more than 20M people in the U.S. The company plans to deliver 100M single-shot vaccines to the U.S. during the first half of 2021. The U.S. government will manage allocation and distribution of the vaccine in the U.S. 2. Warren Buffett Berkshire Hathaway's (BRK.A, BRK.B) fourth quarter profits rose, with its net earnings rising to $38.5B, or $23,015 a Class A share equivalent, up almost 23% from the previous year's profit of $29.2B, or $17,909 a share. Operating earnings, which exclude some investment results, rose to $5 billion from $4.4 billion the year before. Buffett also said in his annual shareholder letter to "never bet against America." "In its brief 232 years of existence... there has been no incubator for unleashing human potential like America," he added. "Despite some severe interruptions, our country's economic progress has been breathtaking. Our unwavering conclusion: Never bet against America." Buffett said the conglomerate owns the biggest amount of U.S. assets by value than any other company in the country. Berkshire Hathaway also bought back a record amount of company stock last year. During the fourth quarter, the company bought back about $9B shares for a total 2020 repurchase of $24.7B. Buffett said in his annual shareholder letter that repurchases have continued since year-end and "is likely to further reduce its share count in the future." 3. Ross Stores (ROST) offers shoppers a chance to find overlooked "treasures" among a heap of discards and its stock could offer investors the same opportunity, Teresa Rivas wrote in this week's edition of Barron's. The company has had a tough time during the pandemic and its stock has took a bigger beating, the author noted. But the underperformance means that Ross also has the most to gain as more vaccines are given and reopening accelerates, Rivas added. 4. Twilio (TWLO) is in talks to invest as much as $750M in Carlyle Group's (CG) Syniverse Technologies in a precursor to a public listing, Cara Lombardo and Dana Cimilluca of Wall Street Journal reported, citing people familiar with the matter. The investment will be announced Monday and could be followed in the coming months by a merger between Syniverse and a special-purpose acquisition company, sources told the Journal. Such a deal could value Syniverse around $2B to $3B including debt, they added. The Twilio deal involves a commercial arrangement that would send a significant amount of business to Syniverse, which provides roaming, messaging and other telecommunications services, the sources said. 5. American Electric Power (AEP), Dominion Energy (D), Entergy (ETR), Exelon (EXC), NextEra Energy (NEE), Citigroup (C), Dow (DOW) and Asos (ASOMY) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

ROST Ross Stores
$116.65 /

-2.08 (-1.75%)

TWLO Twilio
$392.84 /

+15.295 (+4.05%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

AEP American Electric
$74.88 /

-1.43 (-1.87%)

D Dominion
$68.29 /

-2.31 (-3.27%)

ETR Entergy
$86.82 /

-1.26 (-1.43%)

EXC Exelon
$38.60 /

-0.32 (-0.82%)

NEE NextEra Energy
$73.51 /

-0.55 (-0.74%)

C Citi
$65.86 /

-1.54 (-2.28%)

DOW Dow Inc.
$59.32 /

-2.055 (-3.35%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

07/07/20 Argus
Dominion price target lowered to $80 from $87 at Argus
BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

07/07/20 Argus
Dominion price target lowered to $80 from $87 at Argus
07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
ROST Ross Stores
$116.65 /

-2.08 (-1.75%)

01/21/21 Deutsche Bank
Ross Stores price target raised to $129 from $123 at Deutsche Bank
01/04/21 JPMorgan
Ross Stores price target raised to $128 from $125 at JPMorgan
11/20/20 MKM Partners
Ross Stores price target raised to $124 from $105 at MKM Partners
11/20/20 Loop Capital
Ross Stores price target raised to $130 from $110 at Loop Capital
TWLO Twilio
$392.84 /

+15.295 (+4.05%)

02/18/21 Northland
Twilio price target raised to $500 from $390 at Northland
02/18/21 Needham
Twilio price target raised to $500 from $340 at Needham
02/18/21 KeyBanc
Twilio price target raised to $550 from $420 at KeyBanc
02/18/21 Wells Fargo
Twilio price target raised to $525 from $450 at Wells Fargo
CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

02/24/21 Deutsche Bank
Carlyle Group price target raised to $39 from $37 at Deutsche Bank
02/24/21 Barclays
Carlyle Group price target raised to $39 from $36 at Barclays
02/19/21
Fly Intel: Top five analyst upgrades
02/19/21 Credit Suisse
Carlyle Group upgraded to Outperform from Neutral at Credit Suisse
AEP American Electric
$74.88 /

-1.43 (-1.87%)

01/20/21 Guggenheim
American Electric upgraded to Buy from Neutral at Guggenheim
01/14/21 Goldman Sachs
American Electric downgraded to Sell from Neutral at Goldman Sachs
01/12/21
Fly Intel: Top five analyst downgrades
01/12/21 KeyBanc
American Electric downgraded to Sector Weight at KeyBanc
D Dominion
$68.29 /

-2.31 (-3.27%)

01/29/21 Mizuho
Dominion price target raised to $76 from $75 at Mizuho
01/26/21
Fly Intel: Top five analyst upgrades
01/26/21 Wells Fargo
Dominion upgraded to Overweight from Equal Weight at Wells Fargo
01/21/21 Evercore ISI
Dominion upgraded to Outperform from In Line at Evercore ISI
ETR Entergy
$86.82 /

-1.26 (-1.43%)

01/27/21 Mizuho
Entergy price target lowered to $105 from $110 at Mizuho
01/21/21 Evercore ISI
Entergy upgraded to Outperform from In Line at Evercore ISI
11/17/20 Mizuho
Entergy price target raised to $119 from $109 at Mizuho
11/16/20 Wolfe Research
Entergy upgraded to Outperform from Peer Perform at Wolfe Research
EXC Exelon
$38.60 /

-0.32 (-0.82%)

01/06/21 BofA
Exelon upgraded to Buy from Neutral at BofA
12/15/20 BofA
Exelon upgraded to Neutral from Underperform at BofA
12/11/20 Argus
Exelon price target raised to $45 from $42 at Argus
10/26/20
Fly Intel: Top five analyst downgrades
NEE NextEra Energy
$73.51 /

-0.55 (-0.74%)

01/27/21 Credit Suisse
NextEra Energy price target raised to $87 from $77 at Credit Suisse
01/27/21 Wells Fargo
NextEra Energy price target raised to $100 from $85 at Wells Fargo
01/20/21 Credit Suisse
NextEra Energy Partners price target raised to $86 from $71 at Credit Suisse
01/11/21 Mizuho
NextEra Energy price target raised to $90 from $64 at Mizuho
C Citi
$65.86 /

-1.54 (-2.28%)

01/21/21 Berenberg
Berenberg downgrades Citi to Hold after 50% rally
01/21/21 Berenberg
Citi downgraded to Hold from Buy at Berenberg
01/19/21 DA Davidson
Citi price target raised to $84 from $77 at DA Davidson
01/19/21 RBC Capital
Citi price target raised to $73 from $66 at RBC Capital
DOW Dow Inc.
$59.32 /

-2.055 (-3.35%)

02/22/21 BofA
Dow Inc. upgraded to Neutral from Underperform at BofA
02/22/21 BofA
Dow Inc. upgraded to Neutral from Underperform at BofA
02/09/21 Jefferies
Dow Inc. price target raised to $70 from $68 at Jefferies
01/22/21 JPMorgan
Dow Inc. price target raised to $64 from $60 at JPMorgan
ASOMY Asos
$0.00 /

+ (+0.00%)

02/23/21 Grupo Santander
Asos downgraded to Underweight from Hold at Grupo Santander
02/22/21 Barclays
Asos price target raised to 5,750 GBp from 5,150 GBp at Barclays
02/22/21 RBC Capital
Asos price target raised to 7,500 GBp from 6,000 GBp at RBC Capital
02/11/21 Credit Suisse
Asos price target raised to 7,250 GBp from 6,650 GBp at Credit Suisse
JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

ROST Ross Stores
$116.65 /

-2.08 (-1.75%)

TWLO Twilio
$392.84 /

+15.295 (+4.05%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

AEP American Electric
$74.88 /

-1.43 (-1.87%)

D Dominion
$68.29 /

-2.31 (-3.27%)

ETR Entergy
$86.82 /

-1.26 (-1.43%)

EXC Exelon
$38.60 /

-0.32 (-0.82%)

NEE NextEra Energy
$73.51 /

-0.55 (-0.74%)

C Citi
$65.86 /

-1.54 (-2.28%)

DOW Dow Inc.
$59.32 /

-2.055 (-3.35%)

  • 19
    Feb
  • 07
    Aug
JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

ROST Ross Stores
$116.65 /

-2.08 (-1.75%)

TWLO Twilio
$392.84 /

+15.295 (+4.05%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

AEP American Electric
$74.88 /

-1.43 (-1.87%)

D Dominion
$68.29 /

-2.31 (-3.27%)

EXC Exelon
$38.60 /

-0.32 (-0.82%)

NEE NextEra Energy
$73.51 /

-0.55 (-0.74%)

C Citi
$65.86 /

-1.54 (-2.28%)

DOW Dow Inc.
$59.32 /

-2.055 (-3.35%)

ASOMY Asos
$0.00 /

+ (+0.00%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

ROST Ross Stores
$116.65 /

-2.08 (-1.75%)

TWLO Twilio
$392.84 /

+15.295 (+4.05%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

EXC Exelon
$38.60 /

-0.32 (-0.82%)

NEE NextEra Energy
$73.51 /

-0.55 (-0.74%)

C Citi
$65.86 /

-1.54 (-2.28%)

DOW Dow Inc.
$59.32 /

-2.055 (-3.35%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

ROST Ross Stores
$116.65 /

-2.08 (-1.75%)

TWLO Twilio
$392.84 /

+15.295 (+4.05%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

EXC Exelon
$38.60 /

-0.32 (-0.82%)

NEE NextEra Energy
$73.51 /

-0.55 (-0.74%)

C Citi
$65.86 /

-1.54 (-2.28%)

DOW Dow Inc.
$59.32 /

-2.055 (-3.35%)

Periodicals
AstraZeneca sells stake in Moderna for over $1B, The Times reports » 19:59
02/28/21
02/28
19:59
02/28/21
19:59
AZN

AstraZeneca

$48.37 /

-0.53 (-1.08%)

, MRNA

Moderna

$154.90 /

+6.66 (+4.49%)

AstraZeneca (AZN) has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$48.37 /

-0.53 (-1.08%)

MRNA Moderna
$154.90 /

+6.66 (+4.49%)

AZN AstraZeneca
$48.37 /

-0.53 (-1.08%)

02/25/21
Fly Intel: Top five analyst upgrades
02/25/21 UBS
AstraZeneca upgraded to Buy from Neutral at UBS
02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
MRNA Moderna
$154.90 /

+6.66 (+4.49%)

02/26/21 Barclays
Moderna price target raised to $178 from $169 at Barclays
02/26/21 Brookline
Moderna price target raised to $205 from $180 at Brookline
02/25/21 Piper Sandler
Moderna transitioning into profitable company, says Piper Sandler
02/18/21 Jefferies
Moderna price target raised to $180 from $150 at Jefferies
AZN AstraZeneca
$48.37 /

-0.53 (-1.08%)

MRNA Moderna
$154.90 /

+6.66 (+4.49%)

  • 19
    May
AZN AstraZeneca
$48.37 /

-0.53 (-1.08%)

MRNA Moderna
$154.90 /

+6.66 (+4.49%)

AZN AstraZeneca
$48.37 /

-0.53 (-1.08%)

MRNA Moderna
$154.90 /

+6.66 (+4.49%)

AZN AstraZeneca
$48.37 /

-0.53 (-1.08%)

MRNA Moderna
$154.90 /

+6.66 (+4.49%)

Earnings
Liberty Latin America reports Q4 revenue $1.10B, consensus $1.03B » 19:55
02/28/21
02/28
19:55
02/28/21
19:55
LILA

Liberty Latin America

$11.00 /

+0.19 (+1.76%)

, LILAK

Liberty Latin America

$10.97 /

+0.24 (+2.24%)

Reports Q4 adjusted FCF…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LILA Liberty Latin America
$11.00 /

+0.19 (+1.76%)

LILAK Liberty Latin America
$10.97 /

+0.24 (+2.24%)

LILA Liberty Latin America
$11.00 /

+0.19 (+1.76%)

11/05/20 Scotiabank
Liberty Latin America downgraded to Underperform at Scotiabank
11/05/20 Scotiabank
Liberty Latin America downgraded to Underperform from Sector Perform at Scotiabank
10/09/20 Morgan Stanley
Liberty Latin America upgraded to Overweight at Morgan Stanley
03/12/20 HSBC
Liberty Latin America upgraded to Buy from Hold at HSBC
LILAK Liberty Latin America
$10.97 /

+0.24 (+2.24%)

12/04/20 Pivotal Research
Liberty Latin America price target raised to $16 from $13.50 at Pivotal
11/05/20 Scotiabank
Liberty Latin America downgraded to Underperform at Scotiabank
10/08/20 Goldman Sachs
Liberty Latin America upgraded to Buy from Neutral at Goldman Sachs
09/28/20 Scotiabank
Liberty Latin America upgraded to Sector Perform at Scotiabank
LILA Liberty Latin America
$11.00 /

+0.19 (+1.76%)

LILAK Liberty Latin America
$10.97 /

+0.24 (+2.24%)

LILA Liberty Latin America
$11.00 /

+0.19 (+1.76%)

LILA Liberty Latin America
$11.00 /

+0.19 (+1.76%)

Initiation
On24 initiated with a Buy at Goldman Sachs » 19:28
02/28/21
02/28
19:28
02/28/21
19:28
ONTF

On24

$56.34 /

+0.85 (+1.53%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
  • 03
    Feb
ONTF On24
$56.34 /

+0.85 (+1.53%)

Periodicals
Herbalife to name three new directors as Icahn ends investment, WSJ reports » 19:24
02/28/21
02/28
19:24
02/28/21
19:24
HLF

Herbalife Nutrition

$44.98 /

+0.18 (+0.40%)

Herbalife Nutrition plans…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HLF Herbalife Nutrition
$44.98 /

+0.18 (+0.40%)

HLF Herbalife Nutrition
$44.98 /

+0.18 (+0.40%)

12/24/20 Citi
Herbalife Nutrition price target raised to $66 from $63 at Citi
09/11/20 Jefferies
Herbalife, Nu Skin valuation gaps can close as models transform, says Jefferies
06/22/20 Citi
Citi boosts Herbalife target to $63, opens '90 Day Catalyst Watch'
05/08/20 Jefferies
Herbalife Nutrition price target raised to $45 from $40 at Jefferies
HLF Herbalife Nutrition
$44.98 /

+0.18 (+0.40%)

HLF Herbalife Nutrition
$44.98 /

+0.18 (+0.40%)

HLF Herbalife Nutrition
$44.98 /

+0.18 (+0.40%)

Periodicals
Twilio nears up to $750M investment in Syniverse, WSJ reports » 19:20
02/28/21
02/28
19:20
02/28/21
19:20
TWLO

Twilio

$392.84 /

+15.295 (+4.05%)

, CG

Carlyle Group

$34.24 /

-0.22 (-0.64%)

Twilio (TWLO) is in talks…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TWLO Twilio
$392.84 /

+15.295 (+4.05%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

TWLO Twilio
$392.84 /

+15.295 (+4.05%)

02/18/21 Northland
Twilio price target raised to $500 from $390 at Northland
02/18/21 Needham
Twilio price target raised to $500 from $340 at Needham
02/18/21 KeyBanc
Twilio price target raised to $550 from $420 at KeyBanc
02/18/21 Wells Fargo
Twilio price target raised to $525 from $450 at Wells Fargo
CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

02/24/21 Deutsche Bank
Carlyle Group price target raised to $39 from $37 at Deutsche Bank
02/24/21 Barclays
Carlyle Group price target raised to $39 from $36 at Barclays
02/19/21
Fly Intel: Top five analyst upgrades
02/19/21 Credit Suisse
Carlyle Group upgraded to Outperform from Neutral at Credit Suisse
TWLO Twilio
$392.84 /

+15.295 (+4.05%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

  • 19
    Feb
  • 07
    Aug
CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

TWLO Twilio
$392.84 /

+15.295 (+4.05%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

TWLO Twilio
$392.84 /

+15.295 (+4.05%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

Periodicals
CAE near deal to acquire L3Harris military-training unit, WSJ reports » 19:16
02/28/21
02/28
19:16
02/28/21
19:16
CAE

CAE

$26.47 /

-0.57 (-2.11%)

, LHX

L3Harris Technologies

$181.98 /

-4.99 (-2.67%)

CAE (CAE) is nearing a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CAE CAE
$26.47 /

-0.57 (-2.11%)

LHX L3Harris Technologies
$181.98 /

-4.99 (-2.67%)

CAE CAE
$26.47 /

-0.57 (-2.11%)

02/16/21 TD Securities
CAE price target raised to C$34 from C$33 at TD Securities
02/16/21 Scotiabank
CAE price target raised to C$39 from C$38 at Scotiabank
02/16/21 Canaccord
CAE price target raised to C$34 from C$32 at Canaccord
01/04/21 CIBC
CAE price target raised to C$36 from C$33 at CIBC
LHX L3Harris Technologies
$181.98 /

-4.99 (-2.67%)

02/01/21 Credit Suisse
L3Harris Technologies price target lowered to $200 from $210 at Credit Suisse
02/01/21 Citi
L3Harris Technologies price target lowered to $225 from $235 at Citi
01/07/21 Baird
L3Harris Technologies downgraded to Neutral from Outperform at Baird
12/15/20
Fly Intel: Top five analyst downgrades
CAE CAE
$26.47 /

-0.57 (-2.11%)

LHX L3Harris Technologies
$181.98 /

-4.99 (-2.67%)

LHX L3Harris Technologies
$181.98 /

-4.99 (-2.67%)

CAE CAE
$26.47 /

-0.57 (-2.11%)

Periodicals
Macy's, Gap letting customers buy now, pay later, WSJ reports » 18:12
02/28/21
02/28
18:12
02/28/21
18:12
M

Macy's

$15.20 /

-0.505 (-3.22%)

, GPS

Gap

$24.96 /

-0.27 (-1.07%)

, AFRM

Affirm

$93.06 /

-1.135 (-1.20%)

Chains from Macy's…

Chains from Macy's (M) to Gap (GPS) to Neiman Marcus Group have introduced buy now, pay later options in recent months to attract younger shoppers, who are less likely to use credit cards, The Wall Street Journal's Suzanne Kapner reports. The emerging payment option is a modern take on old-fashioned layaway plans, allowing shoppers to pay for purchases over time, the author notes. Instead of earning a profit from customers who revolve a balance on their store cards, retailers pay fees to the financial-technology companies that offer buy now, pay later plans, including Klarna Bank AB, Affirm Holdings (AFRM) and Afterpay, the publication adds. Reference Link

ShowHide Related Items >><<
M Macy's
$15.20 /

-0.505 (-3.22%)

GPS Gap
$24.96 /

-0.27 (-1.07%)

AFRM Affirm
$93.06 /

-1.135 (-1.20%)

M Macy's
$15.20 /

-0.505 (-3.22%)

02/24/21 Credit Suisse
Macy's price target raised to $13 from $7 at Credit Suisse
02/24/21 Deutsche Bank
Macy's price target raised to $16 from $15 at Deutsche Bank
02/18/21 Morgan Stanley
Macy's price target raised to $11 from $6 at Morgan Stanley
01/21/21 Deutsche Bank
Macy's price target raised to $15 from $9 at Deutsche Bank
GPS Gap
$24.96 /

-0.27 (-1.07%)

02/16/21 Jefferies
Gap assumed with a Hold at Jefferies
01/21/21 Deutsche Bank
Gap price target raised to $26 from $25 at Deutsche Bank
01/15/21 B. Riley Securities
Gap price target lowered to $22 from $31 at B. Riley Securities
11/25/20
Fly Intel: Top five analyst downgrades
AFRM Affirm
$93.06 /

-1.135 (-1.20%)

02/16/21 Barclays
Affirm price target raised to $148 from $132 at Barclays
02/12/21 RBC Capital
Affirm price target raised to $155 from $130 at RBC Capital
02/12/21 Morgan Stanley
Affirm price target raised to $146 from $142 at Morgan Stanley
02/08/21
Fly Intel: Top five analyst initiations
M Macy's
$15.20 /

-0.505 (-3.22%)

GPS Gap
$24.96 /

-0.27 (-1.07%)

AFRM Affirm
$93.06 /

-1.135 (-1.20%)

  • 13
    Jan
M Macy's
$15.20 /

-0.505 (-3.22%)

GPS Gap
$24.96 /

-0.27 (-1.07%)

AFRM Affirm
$93.06 /

-1.135 (-1.20%)

M Macy's
$15.20 /

-0.505 (-3.22%)

GPS Gap
$24.96 /

-0.27 (-1.07%)

AFRM Affirm
$93.06 /

-1.135 (-1.20%)

M Macy's
$15.20 /

-0.505 (-3.22%)

GPS Gap
$24.96 /

-0.27 (-1.07%)

AFRM Affirm
$93.06 /

-1.135 (-1.20%)

Periodicals
House approves Biden's $1.9T COVID aid, Reuters reports » 18:08
02/28/21
02/28
18:08
02/28/21
18:08
SPY

SPDR S&P 500 ETF Trust

$380.35 /

-2.04 (-0.53%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

President Joe…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$380.35 /

-2.04 (-0.53%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$380.35 /

-2.04 (-0.53%)

01/07/21 Credit Suisse
Credit Suisse raises 2021 S&P 500 target to 4,200, sees 12% upside
11/09/20 JPMorgan
JPMorgan sees S&P 500 hitting 4,000 by early next year
09/01/20
Fed's Brainard says monetary policy to pivot from stabilization to accommodation
08/17/20 Goldman Sachs
Goldman boosts end of 2020 S&P 500 target to 3,600 from 3,000
SPX S&P 500
$0.00 /

+ (+0.00%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$380.35 /

-2.04 (-0.53%)

SPY SPDR S&P 500 ETF Trust
$380.35 /

-2.04 (-0.53%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$380.35 /

-2.04 (-0.53%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Periodicals
Reliance partners with Google, Facebook for payment network bid, Reuters says » 18:07
02/28/21
02/28
18:07
02/28/21
18:07
FB

Facebook

$257.21 /

+2.63 (+1.03%)

, GOOG

Alphabet

$2,035.58 /

+0.69 (+0.03%)

, GOOGL

Alphabet Class A

$2,020.96 /

+0.6 (+0.03%)

India's conglomerate…

India's conglomerate Reliance Industries has partnered with Facebook (FB), Google (GOOGL) and fintech player Infibeam to set up a national digital payment network, according to Reuters, citing a report by the Economic Times. Last year, India's central bank invited companies to forge new umbrella entities to create a payments network that would rival the system operated by the National Payments Council of India, as it seeks to reduce concentration risks in the space, the report notes. Reference Link

ShowHide Related Items >><<
GOOGL Alphabet Class A
$2,020.96 /

+0.6 (+0.03%)

GOOG Alphabet
$2,035.58 /

+0.69 (+0.03%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

02/26/21 Jefferies
Twitter price target raised to $79 from $64 at Jefferies
02/16/21 Loop Capital
Facebook price target raised to $370 from $330 at Loop Capital
02/10/21 Tigress Financial
Facebook has 'significant upside' at current levels, says Tigress
02/01/21 Truist
Alphabet price target raised to $2,100 from $2,000 at Truist
GOOG Alphabet
$2,035.58 /

+0.69 (+0.03%)

02/17/21 Morgan Stanley
Roku price target raised to $275 from $200 at Morgan Stanley
02/12/21 Citi
Citi boosts Alphabet target but shares no longer a top pick
02/08/21 Stephens
Global Payments merchant business advanced by Google pact, says Stephens
02/03/21 JMP Securities
Alphabet price target raised to $2,400 from $1,700 at JMP Securities
GOOGL Alphabet Class A
$2,020.96 /

+0.6 (+0.03%)

02/17/21 Maxim
Kaleyra price target raised to $30 from $22 at Maxim
02/16/21 Loop Capital
Alphabet upgraded to Buy from Hold at Loop Capital
GOOGL Alphabet Class A
$2,020.96 /

+0.6 (+0.03%)

GOOG Alphabet
$2,035.58 /

+0.69 (+0.03%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

GOOG Alphabet
$2,035.58 /

+0.69 (+0.03%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

GOOG Alphabet
$2,035.58 /

+0.69 (+0.03%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

GOOGL Alphabet Class A
$2,020.96 /

+0.6 (+0.03%)

GOOG Alphabet
$2,035.58 /

+0.69 (+0.03%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

Periodicals
Danone takes step to sell Chinese step amid shareholder pressure, Reuters says » 17:59
02/28/21
02/28
17:59
02/28/21
17:59
DANOY

Danone

$0.00 /

+ (+0.00%)

Danone said on Sunday it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DANOY Danone
$0.00 /

+ (+0.00%)

DANOY Danone
$0.00 /

+ (+0.00%)

02/26/21 Morgan Stanley
Danone assumed with an Equal Weight at Morgan Stanley
02/23/21 Berenberg
Danone price target raised to EUR 60 from EUR 58 at Berenberg
01/26/21 Societe Generale
Danone price target lowered to EUR 47 from EUR 49 at Societe Generale
01/14/21 Deutsche Bank
Danone price target lowered to EUR 62 from EUR 64 at Deutsche Bank
DANOY Danone
$0.00 /

+ (+0.00%)

DANOY Danone
$0.00 /

+ (+0.00%)

Periodicals
Hyatt calls hate symbols 'abhorrent' after CPAC controversy, Reuters says » 17:56
02/28/21
02/28
17:56
02/28/21
17:56
H

Hyatt

$87.93 /

+0.79 (+0.91%)

Hyatt Hotels called…

Hyatt Hotels called symbols of hate "abhorrent" on Sunday after the design of a stage at the Conservative Political Action Conference at one of its hotels drew comparisons to a Norse rune used by Nazis during World War Two, according to Reuters. High-profile Republicans including former President Donald Trump are attending the four-day event in Orlando, Florida, the publication notes. A photo of the CPAC stage went viral on social media on Saturday, with thousands of Twitter users sharing posts comparing its distinctive design to an othala rune, one of many ancient European symbols that Nazis adopted to "reconstruct a mythic 'Aryan' past," according to the Anti-Defamation League. Reference Link

ShowHide Related Items >><<
H Hyatt
$87.93 /

+0.79 (+0.91%)

H Hyatt
$87.93 /

+0.79 (+0.91%)

02/22/21 Evercore ISI
Hyatt price target raised to $90 from $80 at Evercore ISI
02/19/21 Macquarie
Hyatt price target raised to $67 from $46 at Macquarie
02/19/21 Deutsche Bank
Hyatt price target raised to $69 from $49 at Deutsche Bank
02/12/21 Berenberg
Hyatt downgraded to Sell from Hold at Berenberg
H Hyatt
$87.93 /

+0.79 (+0.91%)

H Hyatt
$87.93 /

+0.79 (+0.91%)

Periodicals
McDonald's considering selling part of Dynamic Yield, Bloomberg reports » 17:47
02/28/21
02/28
17:47
02/28/21
17:47
MCD

McDonald's

$206.13 /

-2.27 (-1.09%)

McDonald's said it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MCD McDonald's
$206.13 /

-2.27 (-1.09%)

MCD McDonald's
$206.13 /

-2.27 (-1.09%)

02/22/21 Wells Fargo
Wells Fargo strategist upgrades Consumer Services sector to Overweight
02/01/21 Citi
Citi opens 'Catalyst Watch' on McDonald's into chicken sandwich launch
01/21/21 UBS
UBS sees 'golden' risk reward for McDonald's
01/19/21 Goldman Sachs
McDonald's initiated with a Buy at Goldman Sachs
MCD McDonald's
$206.13 /

-2.27 (-1.09%)

MCD McDonald's
$206.13 /

-2.27 (-1.09%)

MCD McDonald's
$206.13 /

-2.27 (-1.09%)

MCD McDonald's
$206.13 /

-2.27 (-1.09%)

Periodicals
Microsoft says vaccine tools have 'fallen short,' Bloomberg reports » 17:43
02/28/21
02/28
17:43
02/28/21
17:43
MSFT

Microsoft

$232.37 /

+3.21 (+1.40%)

Widely-used Microsoft…

Widely-used Microsoft vaccine scheduling software that has run into difficulties in states like Iowa and New Jersey is being blamed for problems that left some residents of the nation's capital unable to book appointments, Bloomberg's Ari Natter and Dina Bass report. After three straight days of issues with the District of Columbia's online vaccination registration, the company released a statement along with the city government acknowledging "that our efforts have fallen short" and vowing to address the problems, the authors note. "We understand the frustration of individuals who attempted to utilize the District's vaccination appointment portal this week," they said. "We are committed to address technical issues so that the vaccination appointment portal is properly functional and accessible." Reference Link

ShowHide Related Items >><<
MSFT Microsoft
$232.37 /

+3.21 (+1.40%)

MSFT Microsoft
$232.37 /

+3.21 (+1.40%)

02/16/21 Wedbush
Microsoft price target raised to $300 from $285 at Wedbush
02/16/21 UBS
Workday price target raised to $280 from $235 at UBS
02/08/21 KeyBanc
Viva reinforces Microsoft Office/Teams innovation commitment, says KeyBanc
02/08/21 RBC Capital
Datadog price target raised to $110 from $85 at RBC Capital
MSFT Microsoft
$232.37 /

+3.21 (+1.40%)

MSFT Microsoft
$232.37 /

+3.21 (+1.40%)

MSFT Microsoft
$232.37 /

+3.21 (+1.40%)

MSFT Microsoft
$232.37 /

+3.21 (+1.40%)

Hot Stocks
CDC Advisory Committee recommends J&J single-shot COVID vaccine for adults 18+ » 17:41
02/28/21
02/28
17:41
02/28/21
17:41
JNJ

Johnson & Johnson

$158.52 /

-4.28 (-2.63%)

Johnson & Johnson…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

Hot Stocks
BridgeBio, affiliate Origin Biosciences announce FDA approval of NULIBRY » 16:14
02/28/21
02/28
16:14
02/28/21
16:14
BBIO

BridgeBio

$70.63 /

+5.37 (+8.23%)

BridgeBio Pharma and…

BridgeBio Pharma and affiliate Origin Biosciences announced the U.S. Food and Drug Administration has approved NULIBRY for Injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency Type A. This is the first therapy of its kind. The novel therapy was developed based on BridgeBio's commitment to developing a treatment for MoCD Type A in collaboration with the experts and families in the MoCD Type A community. MoCD Type A is an ultra-rare and progressive condition, known to impact less than 150 patients globally with a median survival of four years. MoCD Type A presents shortly after birth, often with severe encephalopathy and intractable seizures. NULIBRY is a first-in-class approved cPMP substrate replacement therapy. The efficacy of NULIBRY for the treatment of patients with MoCD Type A was established based on data from three clinical trials compared to data from a natural history study. In these studies, NULIBRY or recombinant cPMP reduced the risk of death by 82% compared to the untreated, genotype-matched, historical control group in the natural history study. At three years on study, the probability of survival in NULIBRY or rcPMP-treated patients was 84% compared to 55% for untreated genotype-matched patients in the historical control group at three years. In addition to the survival analysis, treatment with NULIBRY led to a reduction of urine concentrations of S-sulfocysteine, a toxic substance that leads to neurological damage, in patients with MoCD Type A, and the reduction was sustained with long-term treatment over 48 months. Animal studies have identified that NULIBRY has phototoxic potential. NULIBRY was reviewed under Priority Review and received Orphan Drug Designation, Breakthrough Therapy Designation and Rare Pediatric Disease Designation from the FDA. With this approval, the FDA also issued a Rare Pediatric Disease Priority Review Voucher to Origin.

ShowHide Related Items >><<
BBIO BridgeBio
$70.63 /

+5.37 (+8.23%)

BBIO BridgeBio
$70.63 /

+5.37 (+8.23%)

02/22/21 JPMorgan
BridgeBio reinstated with an Overweight at JPMorgan
02/09/21
Fly Intel: Top five analyst initiations
02/09/21 Goldman Sachs
BridgeBio reinstated with a Buy at Goldman Sachs
01/11/21 H.C. Wainwright
BridgeBio price target raised to $87 from $64 at H.C. Wainwright
BBIO BridgeBio
$70.63 /

+5.37 (+8.23%)

  • 12
    Feb
  • 29
    May
BBIO BridgeBio
$70.63 /

+5.37 (+8.23%)

BBIO BridgeBio
$70.63 /

+5.37 (+8.23%)

Hot Stocks
Regeneron announces Phase 2 data evaluating antibody cocktail REGN1908-1909 » 16:09
02/28/21
02/28
16:09
02/28/21
16:09
REGN

Regeneron

$450.48 /

-2.29 (-0.51%)

Regeneron Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
REGN Regeneron
$450.48 /

-2.29 (-0.51%)

REGN Regeneron
$450.48 /

-2.29 (-0.51%)

02/23/21 Credit Suisse
Regeneron price target raised to $760 from $753 at Credit Suisse
02/16/21 Cantor Fitzgerald
Regeneron price target lowered to $656 from $696 at Cantor Fitzgerald
02/08/21 SVB Leerink
Regeneron price target raised to $640 from $623 at SVB Leerink
02/08/21 Credit Suisse
Regeneron price target lowered to $753 from $758 at Credit Suisse
REGN Regeneron
$450.48 /

-2.29 (-0.51%)

  • 27
    May
REGN Regeneron
$450.48 /

-2.29 (-0.51%)

REGN Regeneron
$450.48 /

-2.29 (-0.51%)

REGN Regeneron
$450.48 /

-2.29 (-0.51%)

Downgrade
Harvey Norman downgraded to Neutral from Buy at Goldman Sachs » 10:49
02/28/21
02/28
10:49
02/28/21
10:49
HNORY

Harvey Norman

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Andrew McLennan downgraded Harvey Norman to Neutral from Buy with a price target of A$5.10. The analyst acknowledges that Harvey Norman delivered a "very strong" result in the first half of 2021. While conditions were still patchy and unpredictable in parts due to the pandemic, the company benefited substantially from the shift in spending by consumers on products and activities around the home over the first half of 2021 and it managed the business well under volatile, but strong trading conditions, McLennan contends. However, the analyst believes peak trading is unlikely to be sustained.

ShowHide Related Items >><<
HNORY Harvey Norman
$0.00 /

+ (+0.00%)

02/23/21 Credit Suisse
Harvey Norman downgraded to Neutral from Outperform at Credit Suisse
06/10/20 Jefferies
Harvey Norman upgraded to Buy from Hold at Jefferies
On The Fly
Opening Day: Coinbase files to go public » 10:13
02/28/21
02/28
10:13
02/28/21
10:13
FB

Facebook

$257.21 /

+2.63 (+1.03%)

, SCR

Score Media

$27.09 /

-0.91 (-3.25%)

, ARYD

Arya Sciences Acquisition Corp IV

$10.97 /

+0.065 (+0.60%)

, TWLV

Twelve Seas Investment Company II

$0.00 /

+ (+0.00%)

, AUS

Austerlitz Acquisition Corporation I

$0.00 /

+ (+0.00%)

, ASZ

Austerlitz Acquisition Corporation II

$0.00 /

+ (+0.00%)

, FACT

Freedom Acquisition I

$0.00 /

+ (+0.00%)

, SBEA

SilverBox Engaged Merger Corp I

$0.00 /

+ (+0.00%)

, IBER

Ibere Pharmaceuticals

$0.00 /

+ (+0.00%)

, FSNB

Fusion Acquisition Corp. II

$0.00 /

+ (+0.00%)

, AGAC

African Gold Acquisition

$0.00 /

+ (+0.00%)

, EJFA

EJF Acquisition

$0.00 /

+ (+0.00%)

, GLBL

Cartesian Growth

$5.10 /

+ (+0.00%)

, SRNG

Soaring Eagle Acquisition

$0.00 /

+ (+0.00%)

, FTAA

FTAC Athena Acquisition

$0.00 /

+ (+0.00%)

, SLAM

Slam Corp.

$0.00 /

+ (+0.00%)

, GSEVU

Gores Holdings VII

$10.40 /

-0.05 (-0.48%)

, ANAC

Arctos NorthStar Acquisition

$0.00 /

+ (+0.00%)

, COIN

Coinbase

$0.00 /

+ (+0.00%)

, RBLX

Roblox

$0.00 /

+ (+0.00%)

, CPNG

Coupang

$0.00 /

+ (+0.00%)

, HOMS

Caliber Home Loans

$0.00 /

+ (+0.00%)

, PHAR

Pharming

$13.64 /

-0.04 (-0.29%)

, CRCT

Cricut

$0.00 /

+ (+0.00%)

, GROY

Gold Royalty

$0.00 /

+ (+0.00%)

, OSCR

Oscar Health

$0.00 /

+ (+0.00%)

, PLTR

Palantir

$23.88 /

-0.09 (-0.38%)

, ASAN

Asana

$34.66 /

-0.45 (-1.28%)

, WORK

Slack Technologies

$40.97 /

-0.84 (-2.01%)

, SPOT

Spotify

$307.83 /

+4.96 (+1.64%)

, BABA

Alibaba

$237.75 /

-2.35 (-0.98%)

Coinbase, the biggest…

ShowHide Related Items >><<
WORK Slack Technologies
$40.97 /

-0.84 (-2.01%)

SPOT Spotify
$307.83 /

+4.96 (+1.64%)

RBLX Roblox
$0.00 /

+ (+0.00%)

PLTR Palantir
$23.88 /

-0.09 (-0.38%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

COIN Coinbase
$0.00 /

+ (+0.00%)

BABA Alibaba
$237.75 /

-2.35 (-0.98%)

ASAN Asana
$34.66 /

-0.45 (-1.28%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

02/26/21 Jefferies
Twitter price target raised to $79 from $64 at Jefferies
02/16/21 Loop Capital
Facebook price target raised to $370 from $330 at Loop Capital
02/10/21 Tigress Financial
Facebook has 'significant upside' at current levels, says Tigress
02/01/21 Truist
Alphabet price target raised to $2,100 from $2,000 at Truist
SCR Score Media
$27.09 /

-0.91 (-3.25%)

ARYD Arya Sciences Acquisition Corp IV
$10.97 /

+0.065 (+0.60%)

TWLV Twelve Seas Investment Company II
$0.00 /

+ (+0.00%)

AUS Austerlitz Acquisition Corporation I
$0.00 /

+ (+0.00%)

ASZ Austerlitz Acquisition Corporation II
$0.00 /

+ (+0.00%)

FACT Freedom Acquisition I
$0.00 /

+ (+0.00%)

SBEA SilverBox Engaged Merger Corp I
$0.00 /

+ (+0.00%)

IBER Ibere Pharmaceuticals
$0.00 /

+ (+0.00%)

FSNB Fusion Acquisition Corp. II
$0.00 /

+ (+0.00%)

AGAC African Gold Acquisition
$0.00 /

+ (+0.00%)

EJFA EJF Acquisition
$0.00 /

+ (+0.00%)

GLBL Cartesian Growth
$5.10 /

+ (+0.00%)

SRNG Soaring Eagle Acquisition
$0.00 /

+ (+0.00%)

FTAA FTAC Athena Acquisition
$0.00 /

+ (+0.00%)

SLAM Slam Corp.
$0.00 /

+ (+0.00%)

GSEVU Gores Holdings VII
$10.40 /

-0.05 (-0.48%)

ANAC Arctos NorthStar Acquisition
$0.00 /

+ (+0.00%)

COIN Coinbase
$0.00 /

+ (+0.00%)

RBLX Roblox
$0.00 /

+ (+0.00%)

CPNG Coupang
$0.00 /

+ (+0.00%)

HOMS Caliber Home Loans
$0.00 /

+ (+0.00%)

PHAR Pharming
$13.64 /

-0.04 (-0.29%)

CRCT Cricut
$0.00 /

+ (+0.00%)

GROY Gold Royalty
$0.00 /

+ (+0.00%)

OSCR Oscar Health
$0.00 /

+ (+0.00%)

PLTR Palantir
$23.88 /

-0.09 (-0.38%)

02/17/21
Fly Intel: Top five analyst upgrades
02/17/21 RBC Capital
Palantir price target raised to $27 from $15 at RBC Capital
02/17/21 Jefferies
Palantir 'a highly unique story for long-term investors,' says Jefferies
02/17/21 Morgan Stanley
Palantir price target raised to $19 from $17 at Morgan Stanley
ASAN Asana
$34.66 /

-0.45 (-1.28%)

01/15/21 Credit Suisse
Asana assumed with a Neutral at Credit Suisse
01/11/21 Piper Sandler
Bill.com price target raised to $140 from $120 at Piper Sandler
12/10/20 RBC Capital
Asana price target raised to $36 from $30 at RBC Capital
12/10/20 Jefferies
Asana price target raised to $35 from $30 at Jefferies
WORK Slack Technologies
$40.97 /

-0.84 (-2.01%)

12/09/20 Morgan Stanley
Salesforce $50B revenue target unlikely a source of upside, says Morgan Stanley
12/09/20 Canaccord
Salesforce valuation compelling especially on pullback, says Canaccord
12/09/20 Morgan Stanley
Slack Technologies upgraded to Equal Weight from Underweight at Morgan Stanley
12/03/20 Wedbush
Slack Technologies upgraded to Neutral from Underperform at Wedbush
SPOT Spotify
$307.83 /

+4.96 (+1.64%)

02/23/21
Fly Intel: Top five analyst downgrades
02/23/21 JPMorgan
Spotify price target raised to $385 from $350 at JPMorgan
02/23/21 Atlantic Equities
Spotify downgraded to Neutral from Overweight at Atlantic Equities
02/10/21 Pivotal Research
Spotify price target raised to $340 from $260 at Pivotal Research
BABA Alibaba
$237.75 /

-2.35 (-0.98%)

02/23/21 Credit Suisse
Farfetch price target raised to $85 from $53 at Credit Suisse
02/03/21 Raymond James
Alibaba price target raised to $350 from $330 at Raymond James
02/03/21 Mizuho
Alibaba price target raised to $285 from $270 at Mizuho
02/03/21 Macquarie
Alibaba price target raised to $395 from $387 at Macquarie
WORK Slack Technologies
$40.97 /

-0.84 (-2.01%)

SPOT Spotify
$307.83 /

+4.96 (+1.64%)

PLTR Palantir
$23.88 /

-0.09 (-0.38%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

BABA Alibaba
$237.75 /

-2.35 (-0.98%)

ASAN Asana
$34.66 /

-0.45 (-1.28%)

  • 25
    Feb
  • 03
    Mar
  • 29
    Oct
WORK Slack Technologies
$40.97 /

-0.84 (-2.01%)

SPOT Spotify
$307.83 /

+4.96 (+1.64%)

RBLX Roblox
$0.00 /

+ (+0.00%)

PLTR Palantir
$23.88 /

-0.09 (-0.38%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

CPNG Coupang
$0.00 /

+ (+0.00%)

COIN Coinbase
$0.00 /

+ (+0.00%)

BABA Alibaba
$237.75 /

-2.35 (-0.98%)

ASAN Asana
$34.66 /

-0.45 (-1.28%)

WORK Slack Technologies
$40.97 /

-0.84 (-2.01%)

SPOT Spotify
$307.83 /

+4.96 (+1.64%)

RBLX Roblox
$0.00 /

+ (+0.00%)

PLTR Palantir
$23.88 /

-0.09 (-0.38%)

HOMS Caliber Home Loans
$0.00 /

+ (+0.00%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

COIN Coinbase
$0.00 /

+ (+0.00%)

BABA Alibaba
$237.75 /

-2.35 (-0.98%)

ASAN Asana
$34.66 /

-0.45 (-1.28%)

WORK Slack Technologies
$40.97 /

-0.84 (-2.01%)

SPOT Spotify
$307.83 /

+4.96 (+1.64%)

PLTR Palantir
$23.88 /

-0.09 (-0.38%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

BABA Alibaba
$237.75 /

-2.35 (-0.98%)

ASAN Asana
$34.66 /

-0.45 (-1.28%)

Upgrade
Kalbe Farma upgraded to Buy from Neutral at Goldman Sachs » 09:43
02/28/21
02/28
09:43
02/28/21
09:43
PTKFF

Kalbe Farma

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst June Zhu upgraded Kalbe Farma to Buy from Neutral. The analyst expects earnings growth for Kalbe Farma, Indonesia's biggest pharmaceutical and consumer health manufacturer, to break out from the "anemic levels" seen over the past five years. This new growth phase will be driven by less margin pressure for its prescription pharmaceutical business, oncology/biosimilar drugs' local manufacturing scaling up, rising health awareness, and higher distribution sales growth due to COVID treatment drugs and potentially vaccination given its cold-chain storage and extensive coverage, Zhu adds.

ShowHide Related Items >><<
PTKFF Kalbe Farma
$0.00 /

+ (+0.00%)

06/02/20 Morgan Stanley
Kalbe Farma upgraded to Equal Weight from Underweight at Morgan Stanley
Conference/Events
FDA PDUFA Date for Athenex Oraxol (oral paclitaxel) is February 28, 2021  04:55
02/28/21
02/28
04:55
02/28/21
04:55
ATNX

Athenex

$12.18 /

+0.29 (+2.44%)

 
ShowHide Related Items >><<
ATNX Athenex
$12.18 /

+0.29 (+2.44%)

ATNX Athenex
$12.18 /

+0.29 (+2.44%)

02/10/21
Fly Intel: Top five analyst initiations
02/10/21 Evercore ISI
Athenex initiated with an Outperform at Evercore ISI
10/26/20
Fly Intel: Top five analyst initiations
10/26/20 SVB Leerink
Athenex initiated with an Outperform at SVB Leerink
ATNX Athenex
$12.18 /

+0.29 (+2.44%)

  • 10
    Sep
ATNX Athenex
$12.18 /

+0.29 (+2.44%)

Conference/Events
FDA PDUFA Date for CorMedix for Defencath is February 28, 2021  04:55
02/28/21
02/28
04:55
02/28/21
04:55
CRMD

CorMedix

$15.05 /

-0.715 (-4.54%)

 
ShowHide Related Items >><<
CRMD CorMedix
$15.05 /

-0.715 (-4.54%)

CRMD CorMedix
$15.05 /

-0.715 (-4.54%)

02/17/21 Needham
CorMedix initiated with a Buy at Needham
02/09/21 B. Riley Securities
CorMedix price target raised to $25 from $11 at B. Riley Securities
02/02/21 Truist
CorMedix price target raised to $35 from $20 at Truist
09/29/20 JMP Securities
CorMedix initiated with an Outperform at JMP Securities
CRMD CorMedix
$15.05 /

-0.715 (-4.54%)

  • 28
    Jul
Hot Stocks
Johnson & Johnson Covid vaccine granted emergency approval from FDA » 19:15
02/27/21
02/27
19:15
02/27/21
19:15
JNJ

Johnson & Johnson

$158.52 /

-4.28 (-2.63%)

The Food and Drug…

The Food and Drug Administration issued an emergency use authorization for the third vaccine for the prevention of coronavirus disease The EUA allows Johnson & Johnson's Janssen COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older. The FDA has determined that the Janssen COVID-19 Vaccine has met the statutory criteria for issuance of an EUA. The totality of the available data "provides clear evidence that the Janssen COVID-19 Vaccine may be effective in preventing COVID-19," the agency said in a statement. The data also show that the vaccine's known and potential benefits outweigh its known and potential risks, supporting the company's request for the vaccine's use in people 18 years of age and older. The Janssen COVID-19 Vaccine is manufactured using a specific type of virus called adenovirus type 26. The vaccine uses Ad26 to deliver a piece of the DNA, or genetic material, that is used to make the distinctive "spike" protein of the SARS-CoV-2 virus, the FDA said. While adenoviruses are a group of viruses that are relatively common, Ad26, which can cause cold symptoms and pink eye, has been modified for the vaccine so that it cannot replicate in the human body to cause illness, it added. After a person receives this vaccine, the body can temporarily make the spike protein, which does not cause disease, but triggers the immune system to learn to react defensively, producing an immune response against SARS-CoV-2.

ShowHide Related Items >><<
JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

Hot Stocks
Berkshire Hathaway buys back record $25B of company stock in 2020 » 09:24
02/27/21
02/27
09:24
02/27/21
09:24
BRK.A

Berkshire Hathaway

$364,420.00 /

-4355 (-1.18%)

, BRK.B

Berkshire Hathaway

$240.27 /

-3.35 (-1.38%)

Warren Buffett's…

Warren Buffett's Berkshire Hathaway bought back a record amount of company stock last year. During the fourth quarter, the company bought back about $9B shares for a total 2020 repurchase of $24.7B. Buffett said in his annual shareholder letter that repurchases have continued since year-end and "is likely to further reduce its share count in the future." "That action increased your ownership in all of Berkshire's businesses by 5.2% without requiring you to so much as touch your wallet," the letter reads.

ShowHide Related Items >><<
BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

07/07/20 Argus
Dominion price target lowered to $80 from $87 at Argus
07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

Hot Stocks
Berkshire Hathaway sees profit rise 23%, says 'never bet against America' » 09:18
02/27/21
02/27
09:18
02/27/21
09:18
BRK.A

Berkshire Hathaway

$364,420.00 /

-4355 (-1.18%)

, BRK.B

Berkshire Hathaway

$240.27 /

-3.35 (-1.38%)

Warren Buffett Berkshire…

Warren Buffett Berkshire Hathaway's fourth quarter profits rose, with its net earnings rising to $38.5B, or $23,015 a Class A share equivalent, up almost 23% from the previous year's profit of $29.2B, or $17,909 a share. Operating earnings, which exclude some investment results, rose to $5B from $4.4B the year before. Buffett also said in his annual shareholder letter to "never bet against America." "In its brief 232 years of existence... there has been no incubator for unleashing human potential like America," he added. "Despite some severe interruptions, our country's economic progress has been breathtaking. Our unwavering conclusion: Never bet against America." Buffett noted that the conglomerate owns the biggest amount of U.S. assets by value than any other company in the country.

ShowHide Related Items >><<
BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

07/07/20 Argus
Dominion price target lowered to $80 from $87 at Argus
07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.